CluenexUiPath PATH
UiPath scores good on business quality (6.5 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What UiPath does
UiPath sells robotic process automation software, charging enterprises subscription fees to automate repetitive back-office tasks.
- What it does best
UiPath delivers a gross margin of 82.6%, sitting in the top decile of its sector at the 89th percentile. This software pricing power stems from deep enterprise workflow integrations that make switching costs painfully high.
- The main risk
An analyst downgrade following Investor Day signals that growth narratives are failing to impress Wall Street, threatening the valuation multiple if enterprise software adoption slows down.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins sit at 9.2% alongside a 21.0% net margin, reflecting solid conversion from its $1.7B top line. The business gains operating leverage as enterprise software scale increases.
The software relies on enterprise workflow lock-in, placing its gross margin at the 89th sector percentile. However, mediocre moat scoring points to intense competition from major cloud platforms trying to copy core features.
Revenue grew 12.7% to reach $1.7B over the latest period, continuing a steady climb from $1.1B in 2023 but decelerating from historical highs.
With zero debt and $1.5B in cash offsetting liabilities entirely, the balance sheet is pristine. Free cash flow hit $363M, showing the business is getting steadily stronger.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on PATH
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
UiPath scores good on the Cluenex quality check (6.5 of 10), measured against its own industry. Profitability is fair, moat fair, growth steady and financial health strong.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Dec 1, 2026, after the close.
See PATH today
- Today's verdict on PATH, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “UiPath (PATH)”, https://cluenex.com/stocks/path/, data as of Oct 10, 2026.